Amgen and Roche end EPO patent infringement dispute

Roche has admitted the infringement and validity of Amgen's EPO Patents. Court has entered Permanent Injunction and Roche would launch its pegylated-erythropoietin (peg-EPO) product in the US market in mid-2014. The final judgement and injunction was entered by US District Court in Boston against Roche prohibiting Roche from infringing Amgen's patents on recombinant erythropoietin (EPO), thus bringing the five-year patent infringement dispute to an end. Roche conceded with the decision that the five Amgen EPO patents involved in the lawsuit are valid, enforceable and infringed by Roche's pegylated-erythropoietin (peg-EPO) product MIRCERA. The settlement terms do not include any financial payments between the parties.